Near Infrared Photobiomodulation Treatment for Diabetic Macular Oedema

NACompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 19, 2016

Primary Completion Date

February 15, 2019

Study Completion Date

February 15, 2019

Conditions
Diabetic Macular Oedema
Interventions
DEVICE

Ellex Integre NIR laser

"Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.~The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period."

Trial Locations (1)

2000

Sydney Eye Hospital, Sydney

All Listed Sponsors
lead

University of Sydney

OTHER

NCT02181400 - Near Infrared Photobiomodulation Treatment for Diabetic Macular Oedema | Biotech Hunter | Biotech Hunter